Insulet Corp (PODD)
171.40
+2.22
(+1.31%)
USD |
NASDAQ |
Mar 28, 16:00
171.27
-0.13
(-0.08%)
After-Hours: 20:00
Insulet Enterprise Value: 12.70B for March 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 28, 2024 | 12.70B |
March 27, 2024 | 12.54B |
March 26, 2024 | 12.29B |
March 25, 2024 | 12.23B |
March 22, 2024 | 12.20B |
March 21, 2024 | 12.36B |
March 20, 2024 | 12.40B |
March 19, 2024 | 12.64B |
March 18, 2024 | 12.72B |
March 15, 2024 | 12.31B |
March 14, 2024 | 12.44B |
March 13, 2024 | 12.99B |
March 12, 2024 | 13.43B |
March 11, 2024 | 13.38B |
March 08, 2024 | 13.27B |
March 07, 2024 | 12.98B |
March 06, 2024 | 12.30B |
March 05, 2024 | 12.17B |
March 04, 2024 | 12.45B |
March 01, 2024 | 12.55B |
February 29, 2024 | 12.18B |
February 28, 2024 | 12.15B |
February 27, 2024 | 12.36B |
February 26, 2024 | 12.52B |
February 23, 2024 | 13.59B |
Date | Value |
---|---|
February 22, 2024 | 14.50B |
February 21, 2024 | 14.17B |
February 20, 2024 | 14.15B |
February 16, 2024 | 14.07B |
February 15, 2024 | 14.03B |
February 14, 2024 | 13.91B |
February 13, 2024 | 13.99B |
February 12, 2024 | 14.14B |
February 09, 2024 | 14.17B |
February 08, 2024 | 14.46B |
February 07, 2024 | 14.61B |
February 06, 2024 | 14.67B |
February 05, 2024 | 14.24B |
February 02, 2024 | 14.28B |
February 01, 2024 | 14.37B |
January 31, 2024 | 14.05B |
January 30, 2024 | 14.14B |
January 29, 2024 | 14.65B |
January 26, 2024 | 14.38B |
January 25, 2024 | 14.60B |
January 24, 2024 | 14.78B |
January 23, 2024 | 14.99B |
January 22, 2024 | 15.11B |
January 19, 2024 | 15.00B |
January 18, 2024 | 14.97B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.183B
Minimum
Apr 18 2019
23.79B
Maximum
May 12 2023
15.75B
Average
16.40B
Median
Enterprise Value Benchmarks
Haemonetics Corp | 5.011B |
Abbott Laboratories | 204.85B |
Becton Dickinson & Co | 86.42B |
Boston Scientific Corp | 108.96B |
Stryker Corp | 146.03B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 103.30M |
Revenue (Quarterly) | 509.80M |
Total Expenses (Quarterly) | 403.40M |
EPS Diluted (Quarterly) | 1.44 |
Gross Profit Margin (Quarterly) | 70.85% |
Profit Margin (Quarterly) | 20.26% |
Earnings Yield | 1.70% |
Operating Earnings Yield | 1.72% |
Normalized Earnings Yield | 1.698 |